Back to top
more

NeoGenomics (NEO)

(Delayed Data from NSDQ)

$17.17 USD

17.17
746,651

-0.33 (-1.89%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $17.19 +0.02 (0.12%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

5 Healthcare Bets to Stay in Investors Good Books Next Year

by Zacks Equity Research

Based on a few key factors, we zero in on five stocks that show promise to retain the bull run in 2019.

QIAGEN Partners With Novartis to Expand CDx Tests Suite

by Zacks Equity Research

QIAGEN (QGEN) progresses well with the strategy to expand through strategic collaborations. The latest tie up will boost the company's companion diagnostic portfolio.

Is NeoGenomics (NEO) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (NEO) Outperforming Other Medical Stocks This Year?

QIAGEN (QGEN) Partners NeoGenomics to Widen CDx Tests Reach

by Zacks Equity Research

The tie-up with NeoGenomics is expected to enable QIAGEN (QGEN) and pharmaceutical partners streamline the development and introduction of targeted drugs and companion diagnostics.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 29th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

Eyenovia Initiates Phase III Study for Mydriasis Candidate

by Zacks Equity Research

Eyenovia (EYEN) starts enrollment in the first phase III study of a two clinical study program to evaluate its mydriasis candidate, MicroStat. Stock rallies.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for November 20th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Top Ranked Momentum Stocks to Buy for November 9th

by Zacks Equity Research

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 9th

NeoGenomics (NEO) Q3 Earnings and Revenues Top Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 66.67% and 4.36%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

NeoGenomics (NEO) Q3 Earnings Preview: How Are Events Shaping Up?

by Zacks Equity Research

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

EBS vs. NEO: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

EBS vs. NEO: Which Stock Is the Better Value Option?

    EBS vs. NEO: Which Stock Is the Better Value Option?

    by Zacks Equity Research

    EBS vs. NEO: Which Stock Is the Better Value Option?

      Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding

      by Zacks Equity Research

      Zacks.com featured highlights: Live Nation Entertainment, NeoGenomics, Salesforce.com, Paycom Software and Covanta Holding

        Moving Average Crossover Alert: NeoGenomics (NEO)

        by Zacks Equity Research

        NeoGenomics, Inc. (NEO) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

          Kevin Matras headshot

          Explosive Returns with the Filtered Zacks Rank 5 Strategy

          by Kevin Matras

          Kevin Matras goes over the Filtered Zacks Rank 5 strategy. Learn how it can help you pick the best of the Zacks #1 Rank stocks. Highlighted stocks include CVGI, NEO and NTES.